-Reuters
Reported Late Tuesday March 14, Deciphera Pharmaceuticals Announces QINLOCK Included In NCCN Guidelines For The Treatment Of Second-Line GIST Patients And FDA Grants Breakthrough Therapy Designation For QINLOCK In Second-Line GIST Patients With Mutatio…
– NCCN Guidelines Include QINLOCK as a Preferred Regimen for Second-Line GIST Patients Intolerant to Sunitinib –
